Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Essai CheckMate 141 | monsite-1
CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as ...
Figure 2, CheckMate 274 Study Design Schematic - Nivolumab (Opdivo ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus ...
(PDF) Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo ...
ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab ...
CheckMate 77T Trial: Perioperative Nivolumab Plus Chemotherapy in Stage ...
FDA Approval: Perioperative Nivolumab + Chemotherapy - CheckMate 77T ...
ASCO 2020: Biomarker Analyses from the Phase III CheckMate 214 Trial of ...
ESMO 2024: Health-Related Quality of Life from the CheckMate 901 Trial ...
Optimizing the Treatment of Recurrent/Metastatic SCCHN - ppt download
Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell ...
Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M ...
Nivolumab versus standard, single-agent therapy of investigator's ...
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell ...
(PDF) Nivolumab versus investigator’s choice in patients with recurrent ...
(PDF) Efficacy of Nivolumab for Head and Neck Cancer Patients with ...
NEJM on Twitter: "Original Article: Nivolumab for Recurrent Squamous ...
(PDF) Long-term Outcomes with Nivolumab as First-line Treatment in ...
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary ...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of ...
Nivolumab treatment beyond RECIST‐defined progression in recurrent or ...
(PDF) Nivolumab treatment beyond RECIST-defined progression in ...
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary S ...
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV ...
DailyMed - OPDIVO- nivolumab injection
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
ASCO GU 2020: Overall Survival and Independent Review of Response in ...
Nivolumab improves survival in head and neck squamous cell carcinoma ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
Adjuvant nivolumab improves disease-free survival in patients with ...
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent ...
Figure 1 from Nivolumab versus investigator’s choice in patients with ...
Essential Concepts in Harnessing the Immune System in Head and Neck ...
Immune-Mediated Treatment in Head and Neck Cancer: Transforming Care ...
Table 1 from Nivolumab versus investigator’s choice in patients with ...
Two‐year follow‐up of a randomized phase III clinical trial of ...
(PDF) Nivolumab vs investigator’s choice in recurrent or metastatic ...
Nivolumab vs investigator’s choice in recurrent or metastatic squamous ...
Comparison between CheckMate-141 and KEYNOTE-040 phase III trials in ...
(PDF) Nivolumab plus ipilimumab versus sunitinib for first-line ...
Evolving Concepts in the Management of Head and Neck Cancers - ppt download
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate ...
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in ...
(PDF) 1043OTreatment beyond progression with nivolumab in patients with ...
ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究 ...
Nivolumab for recurrent or metastatic head and neck cancer patients ...
Final analysis of nivolumab plus cabozantinib for advanced renal cell ...
(PDF) Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line ...
(PDF) Nivolumab versus standard, single-agent therapy of investigator's ...
Nivolumab in Sorafenib-Experienced Patients With Advanced ...
Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell ...
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum ...
Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and ...
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell ...
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal ...
ASCO GU 2024: Adjuvant Nivolumab Monotherapy vs Placebo for Localized ...
Surgical Outcome Data Reported for CheckMate-816
(PDF) Nivolumab plus radiotherapy with or without temozolomide in newly ...
Opdivo (Nivolumab Injection): Side Effects, Uses, Dosage, Interactions ...
Characteristics of Patients With RECIST-Defined Progression Treated ...
ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line ...
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma ...
FDA批准Nivolumab，肝癌开启免疫治疗新时代-MedSci.cn
EQ-5D-3L: Adjusted LS mean difference (95% CI) between nivolumab and ...
Highlights on 1L nivolumab + chemo for metastatic urothelial carcinoma ...
Nivolumab plus radiotherapy with or without temozolomide in newly ...
(PDF) Nivolumab in patients with advanced hepatocellular carcinoma ...
(PDF) First-line nivolumab plus ipilimumab or chemotherapy versus ...
Characteristics of Patients Stratified by HNC Primary Site | Download ...
(PDF) 361O Patient-reported outcomes (PROs) in recurrent or metastatic ...
(PDF) Effect of Nivolumab vs Bevacizumab in Patients With Recurrent ...
First-line nivolumab plus ipilimumab with two cycles of chemotherapy ...
Nivolumab in patients with metastatic DNA mismatch repair-deficient or ...
Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft ...
Figure 1 from Nivolumab in recurrent/metastatic head and neck cancers ...
Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast Cancer
郭晔教授：免疫治疗成复发转移性头颈鳞癌二线新标准；探索不断向前，施展全线“武力” - 知乎
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line ...
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With ...
(PDF) Neoadjuvant nivolumab for patients with resectable HPV-positive ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
30421-7/asset/08d7fdcd-555d-416c-9ce2-ffb3109d75fb/main.assets/gr3_lrg.jpg)
30421-7/asset/23972897-d1f8-4c6d-8c64-30157b470e3c/main.assets/gr4_lrg.jpg)
30421-7/asset/beee2b88-cdb5-4636-9121-4c7b480d1c60/main.assets/gr2_lrg.jpg)
30700-9/asset/f3717807-dfe2-46cb-a919-17fab708ffa6/main.assets/gr1.gif)
02574-0/asset/44913851-e080-49e4-a451-eb27da4ff784/main.assets/gr1_lrg.jpg)
